Purpose: Studies on drugs selected to target myopia development often use the vehicle-treated fellow eye as a control. However, it is not clear how much of the drug reaches the fellow eye, rendering it a potentially invalid control. Therefore, in this study, pupil responses were used to probe the effects of atropine in both eyes in mice, after unilateral topical application. In a second experiment, interocular differences in refractive development and axial eye growth were studied while atropine was applied daily to one eye. Methods: In 20 C57BL/6 (B6) wildtype mice, a single drop of 1% atropine solution was instilled into one eye. Mice were gently restrained by holding their necks while video image processing software detected the pupil and measured its diameter at a sampling rate of 30 Hz. A bright green LED, attached to the photoretinoscope of the video camera, was flashed. Pupil responses were quantified daily over a period of 2 weeks. In another group of 24 mice, one drop of 1% atropine was applied daily for 28 days. Axial length was measured pre-and post-treatment, using low coherence interferometry (the Zeiss AC-Master). Refractive development was measured by infrared photorefraction. Results: Similar to previous findings with the same device, untreated eyes displayed a pupil constriction of 24.84 ± 1.73% upon stimulation with the green LED. A single drop of 1% atropine caused complete suppression with no significant recovery over the whole observation period of two weeks. The responses in the fellow eye were temporarily reduced to about 75% and then recovered towards baseline. After daily atropine application, there was significant reduction in axial length of the eyes, relative to the saline-treated fellow eyes (3.234 ± 0.186 versus 3.378 ± 0.176 mm, n = 24, p < 0.01, paired t-test) and the refractions became more hyperopic/less myopic (+13.46 ± 2.15 D versus +10.06 ± 2.02 D, n = 24, p < 0.01). Conclusions: In line with previous findings, one drop of atropine solution caused a long lasting suppression of pupil responses in the mouse eye. New data show that the transfer to the fellow eye was limited, making interocular comparisons feasible. It is also new that topical atropine reduced axial eye growth even when mice had largely normal vision.
Introduction
Atropine, a pan muscarinic antagonist is used against myopia progression in children (Chua, Balakrishnan, Tan, & Chan, 2003) but the intervention is still in an experimental state. A study with different concentrations (0.1-1%) of atropine eye drops showed significantly lower progression rates compared to the control group. However, higher doses of atropine were associated with disturbing side effects as mydriasis, photophobia, blurred vision, allergic dermatitis and systemic interference (Shih, Chen, & Chou, 1999; Shih, Hsiao, & Lin, 2000; Yen, Liu, & Kao, 1989) . Lower doses were better tolerated (Shih et al., 1999) . Long-term side effects are still not well studied (Saw, Gazzard, Au Eong, & Tan, 2002) . A study in Taiwan, involving 188 participants found that atropine, combined with multi-focal lenses, retarded the progression rates of myopia (Shih et al., 2001 ) although the mixed treatment makes it difficult to evaluate the effects of atropine alone.
A larger study was initiated more recently named the ''Atropine in the Treatment of Myopia (ATOM) study", which is a randomized, double-masked, placebo-controlled clinical trial to assess the safety and efficacy of atropine eye drops in controlling the progression of myopia in Singapore children (conducted by the Singapore Eye Research Institute). It was confirmed that atropine treatment represents an effective way of reducing axial eye elongation during myopia development. A recent review by Morgan and Megaw (2004) concluded that atropine is currently the most effective drug against myopia. Therefore, it is important to better understand how it prevents axial eye elongation.
Atropine has been extensively tested in animal models. Suppression of deprivation myopia was studied in chicks (McBrien, Moghaddam, & Reeder, 1993; Schwahn, Kaymak, & Schaeffel, 2000) , rhesus monkeys (Tigges et al., 1999; Young, 1965) and tree shrews (McKanna & Casagrande, 1981) . Since the mouse has recently been used as a new model to study myopia (Barathi, Boopathi, Yap, & Beuerman, 2008; Schaeffel, Burkhardt, Howland, & Williams, 2004) , the effects of atropine on pupil responses and eye growth were studied further. It was found (Schaeffel & Burkhardt, 2005 ) that a single drop has a long-lasting effect on light induced pupil responses.
Since the fellow eye is often used as a control eye for drug treatments, it is important to determine how selective the drug is for the treated eye. Furthermore, it had not been studied before in the mouse model or any other animal model whether topical application of atropine (rather than intravitreal injection) in one eye can affect axial eye growth and refractive development, relative to the other eye.
Materials and methods

Animals
A common black mouse strain, C57BL/6 (n = 20), was obtained from Charles River GmbH, Sulzfeld, Germany and bred in the animal facilities of the University of Tuebingen. In addition, C57BL/6 mice (n = 30) were obtained from the animal holding unit of the National University of Singapore, which originally also originated from Charles River. Therefore, data from both were pooled. Animals were housed in groups of six to eight. All mice were raised under a 12-h light/12-h dark cycle. Their treatment was approved by the University Commission of Animal Welfare in Tuebingen as well as by SingHealth IACUC, and was in accordance with the ARVO resolution for care and use of laboratory animals.
Treatment and numbers of animals
In the first experiment, a single drop of 1% atropine solution was instilled into one eye in the morning of the first experimental day. Twenty mice, 35 days old, were used for this study. In the second experiment, a single drop of 1% atropine solution was instilled into the same eye of eight mice every morning for 2 weeks and 16 mice every morning for 4 weeks. A drop had a measured volume of 33 ll and contained 330 lg atropine sulfate at a concentration of 1%. In both experiments, the eyes were treated randomly with some mice receiving atropine eye drops in the right and some in the left eyes. In addition, an untreated control group of six mice, 35 days old, was taken as reference. For the measurements, the mice were placed on a small, elevated wooden platform and gently restrained by holding their necks.
Measurements of the pupil responses and refractive states
Pupillography and measurements of refractive state were performed using infrared photorefraction, performed at 30 Hz sampling rate from a distance of 60 cm in a dim room (ambient illuminance about 0.3 lux). This technique uses the light of infrared light emitting diodes to create a brightness gradient in the pupil of the mouse that is dependent on the refractive error relative to the camera (Schaeffel et al., 2004) . The brightness gradient is automatically quantified by digital video image processing. Pupillary responses were elicited by a high power green LED (5 mm diameter, 16 cd, peak emmission 520 nm, radiation angle 30°, Conrad Electronics, Hirschau, Germany) attached to the retinoscope which was controlled from the computer keyboard via a USB to serial port converter (Schaeffel & Burkhardt, 2005) . Stimulation time was 80 ms. The pupil traces were automatically analyzed by a custom-written software which evaluated the average pupil size in four measurements before the stimulation and at the point of maximal constriction, and which also determined the latency and the time until the constriction was maximal.
In the first experiment, pupillary responses and refractions were determined after 0.16 h, 0.5 h, 1 h, 3 h, 6 h, 24 h, 36 h, 48 h, 54 h, 72 h, 120 h, 144 h, 168 h, 192 h, 240 h, 336 h. In the second experiment, pupillary responses and refractions were measured before and after the daily treatment cycle with atropine, and after 3 h, 168 h, 336 h, 504 h and 672 h.
Measurement of ocular dimensions
Ocular biometry in the mouse eye requires high spatial resolution since one diopter of refractive error is equivalent to only about 6 lm (schematic eye modelling: Schmucker & Schaeffel, 2004a) or 24 lm in axial length difference (regression analysis using experimental data: Barathi et al., 2008) . Low coherence laser interferometry was used (the Zeiss Meditec ACMaster, Carl Zeiss, Jena) to measure axial lengths before and after atropine treatment. The device was originally developed for high-resolution biometry in the anterior segment of human eyes, but can also resolve differences of only about 10 lm in axial eye length in living mice. Details on the method were previously described (Schmucker & Schaeffel, 2004b) .
Results
Effect of single drop of 1% atropine
The average pupil constrictions of six untreated wildtype mice were 24.84 ± 1.73%, with an average pupil size before the stimulation of 2.20 ± 0.18 mm. An original trace is shown in Fig. 1 .
Analysis of the ranges of pupillary responses in untreated naive mice showed that there were no developmental changes in the constriction amplitudes over time. The duration of complete recovery from mydriasis was estimated by fitting a least square regression through the pupil constriction amplitudes over time and calculating at which time the regression intersected the 24.84% line, which represented the full amplitude observed in untreated mice. Surprisingly, in the eyes treated with atropine, no significant recovery occurred over the observation period of 2 weeks. The responses in the fellow eyes were reduced to 75% over a period of up to 3 h and recovered only very slowly to baseline (> 300 h, Fig. 2) . Fig. 1 . Original pupil trace as recorded with the infrared photorefractor. In the bottom, the occurrence of a 80 ms green flash is marked by a vertical line.
Treatment with a single drop of 1% atropine daily, continued over 4 weeks
In this treatment group, the pupillary responses were completely suppressed in the treated eye and some suppression was also noted in the untreated fellow eyes. If the treatment was extended, the pupillary responses in the saline-treated fellow eyes were further reduced over time, suggesting that the atropine effects slowly accumulated (Fig. 3) .
A comparison of the pupil responses in the saline-treated fellow eyes of mice that had received daily atropine versus those which received only one drop at the beginning showed also significant differences at 3 h, 168 h and 336 h (15.98 ± 0.98% versus 18.03 ± 1.02%; 13.50 ± 0.78% versus 19.26 ± 1.12%; 11.53 ± 1.13% versus 21.84 ± 0.86%; p < 0.01 in all cases).
Nevertheless, the pupil responses in the saline-treated remained significant over the entire treatment period, suggesting that a gradient of atropine concentrations between both eyes was maintained. Therefore, an interocular comparison of refractive development and eye growth appeared feasible and was attempted as described below.
Development of refractive state and axial eye growth with daily atropine
At the begin of the treatment period of the second group of mice, selected for daily atropine application, the right eyes had a tendency to be longer than the left eyes before the treatment started (n = 24, p = 0.106; Fig. 4A ). Nevertheless, eyes were randomly selected for either saline or atropine treatment. After 2 weeks, axial lengths were shorter in the atropine treated eye (3.309 ± 0.183 mm) as compared to their saline-treated fellow eyes (3.338 ± 0.162 mm, Fig. 4A ). In an unpaired t-test, this was significant (n = 24, p < 0.05). Sixteen mice were further treated for another 2 weeks. In this case, axial eye growth was even more inhibited by atropine (3.278 ± 0.196 versus 3.365 ± 0.148 mm after 3 weeks; 3.234 ± 0.186 versus 3.378 ± 0.176 mm after 4 weeks, n = 16, p < 0.01).
Refractive state was recorded before and after the treatment period using infrared photorefraction. In line with other published data originating from a similar photorefractor (e.g. Pardue et al., 2008) , mice were mildly hyperopic without treatment (Fig. 4B) . At the end of the treatment period, refractive state of the atropine treated eyes (+13.46 ± 2.15 D) was significantly more hyperopic/ less myopic than in the saline-treated fellow eyes (+10.06 ± 2.02 D, p < 0.01, n = 16). In the atropine-treated eyes, the pupils were more dilated than in their fellow eyes (2.61 ± 0.02 versus 2.32 ± 0.05 mm; p < 0.001).
Developmental changes in refractive error in atropine-treated and saline-treated fellow eyes before and every 2 days after the beginning of atropine installation are shown in Fig. 5 . Fig. 2 . Average pupil constrictions in percent, elicited by a 80 ms flash of green light, at different times after unilateral application of 1% atropine eye drops. After atropine application, the pupillary response was completely suppressed in the treated eye and also some suppression was noticed in the vehicle treated fellow eye. The horizontal line on the top represents the amplitudes of pupil responses in normal mice of the same colony. Error bars denote SEMs (n = 20 mice in the treated group, and 6 untreated mice). Fig. 3 . While the pupil responses in the eyes that received atropine every day where largely absent (black sockets of the bars), the responses in the fellow eyes also declined with the total duration of atropine treatment. This suggests that the atropine effects slowly accumulated (n = 24 in 3, 168 h, 336 h and n = 16 in 504 h, 672 h. Fig. 4 . Before the treatment period, no significant differences were found between both eyes (gray columns on the right). After two and four weeks of daily instillation of 1% atropine solution, the treated eyes remained shorter than the saline-treated fellow eyes (A) and were more hyperopic/less myopic (B). Error bars represent SEMs. Significance levels *p < 0.05, **p < 0.01 (n = 16 animals).
Discussion
Special features of the mouse model in drug screenings for myopia
This study has shown that topical application of 1% atropine solution in one eye reduced pupil responses in both eyes, although too much lesser extend in the vehicle-treated fellow eye. Large differences in pupil responses persisted even if atropine was applied on a daily regimen, indicating that a gradient in atropine concentrations was maintained over the observation period of 2-3 weeks. Accordingly, it is feasible to compare refractive development and axial eye growth in both eyes when atropine is applied unilaterally. A significant suppression of axial eye growth was observed in the atropine-treated eyes, compared to saline-treated fellow eyes. This result encourages further studies with drugs in mice. Furthermore, a low number of individuals (n = 24) were sufficient to show significant differences between both eyes. Perhaps even more encouraging is that axial eye growth was inhibited by topical application of atropine and not by intravitreal injection -which is necessary in other animal models like the chicken. A special case in the mouse is also that axial eye growth is inhibited by atropine even when vision was largely normal (neglecting potential optical effects of cycloplegia). In other animal models, the growth-inhibiting effects of atropine show up most clearly when the eye was deprived of sharp vision (e.g. McBrien et al., 1993) . It is possible that retinal image processing is not so important emmetropization in mice, so that refractive errors can develop during drug treatment without that emmetropization attempts to compensate the error signal.
Optimal concentrations of atropine for cycloplegia in mice
In an earlier study, three different concentrations of atropine were tested in the mouse eyes to induce an optimal effect on the pupil response. All three tested concentrations (0.1%, 0.5%, or 1%) had severe effects on pupil responses in the treated eye but the time of recovery towards baseline was dependent on the concentrations (Schaeffel & Burkhardt, 2005) . In the present study, only the highest dose was tested because it was assumed that potential effects of atropine on the contra-lateral eye would show up most clearly.
Use of atropine and antimuscarinic therapy for myopia retardation
To date atropine has shown to be a promising pharmacological agent that has significantly reduced the progression of myopia in several clinical trials (Shih et al., 1999; Chou, Shih, Ho, & Lin, 1997 , and others) However, the molecular basis of atropine action is yet to be established. Previous analyses agree that the required doses of atropine are much too high to assume a muscarinic receptor-mediated mechanism. This assumption receives further support by the observation that atropine is extremely effective on the pupil in mice (Schaeffel & Burkhardt, 2005) , but has effects on eye growth only at very high doses (this study).
Scleral connective tissue and muscarinic receptors
In this study we have found that the axial length is only slightly reduced in the treated eyes by daily atropine treatment for 2 weeks. It was further reduced if the treatment was continued for another week. There is extensive literature on animal and human myopia studies, but the role of muscarinic receptors remains uncertain (Chua et al., 2006) . At least, other muscarinic antagonists were also found effective although, again, the required doses were very high (pirenzepine: Tan, Lam, Chua, Shu-Ping, & Crockett, 2005) . Axial elongation is believed to have been mediated by alterations in the connective tissues of the sclera (McBrien & Gentle, 2001; Raghunath et al., 1999) , the fibrous coat in the eye. Hence, modulation of connective tissue molecules in the sclera may represent a strategy for arresting all types of myopia development, regardless of the initiating stimulus. It was shown that application of atropine reduces the production of scleral extracellular proteins. Anti-muscarinic drugs were able to change collagen and other structural molecules in animal models of myopia (Lind, Chew, Marzani, & Wallman, 1998; McBrien, Metlapally, Jobling, & Gentle, 2006) . This also suggests that investigation of scleral remodeling by atropine in the mouse model may be a good strategy to discover other anti-myopiagenic drugs for humans.
Conclusions
In mice, atropine caused a long lasting suppression of pupillary responses in treated eyes with little transfer to the saline-treated fellow eyes. Eyeball enlargement was significantly reduced by atropine if continued for 2 weeks or longer, and this happened even when the mice had largely normal vision. That no intravitreal application was necessary, and the effects were significant with a relatively low number of mice, appears promising. The blockade of parasympathetic synaptic transmission in the ciliary muscle by atropine is extremely effective, compared to its inhibition of myopia development -both in animal models and children. This suggests that different mechanisms or receptor types are involved in mydriasis versus myopia suppression.
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